Literature DB >> 12014634

Resistance to p53-mediated growth suppression in human ovarian cancer cells retain endogenous wild-type p53.

X Jin1, W Burke, K Rothman, J Lin.   

Abstract

Cancer cells containing mutated p53 are sensitive to the re-introduction of the wild-type (wt) p53. We sought to determine whether ovarian cancer cells that retain wt p53 are sensitive to the re-introduction of wt p53. Our results demonstrated that A2780 and PA-1 cells, which retain wt p53, are more resistant to apoptosis and growth suppression induced by exogenous expression of wt p53 than SKOV-3 and Caov-3 cells that contain mutated p53. All cell lines, except PA-1, showed induction of the p53-targeted genes. Further, inhibitors of p53-dependent apoptosis, mdm2 and Bcl-xL were not overexpressed in A2780 and PA-1 cells. These results suggest that one major defect in PA-1 cells is due to abrogation of induction of the p53-targets which is independent of mdm2 and Bcl-xL. Although A2780 cells showed induction of the p53-targeted genes, the cleavage of caspase-9 was undetectable. Therefore, p53-dependent apoptosis may be blocked upstream or at the caspase-9 level in A2780 cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12014634

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro.

Authors:  X He; M Pool; K M Darcy; S B Lim; N Auersperg; J S Coon; W T Beck
Journal:  Oncogene       Date:  2007-02-19       Impact factor: 9.867

2.  p150(Sal2) is a p53-independent regulator of p21(WAF1/CIP).

Authors:  Dawei Li; Yu Tian; Yupo Ma; Thomas Benjamin
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

3.  Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IκB.

Authors:  Deok-Soo Son; Syder M Kabir; Yuan-Lin Dong; Eunsook Lee; Samuel E Adunyah
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.